CD266 (FN14), Human/Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD266 (FN14), Human/Mouse antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD266 (FN14), Human/Mouse |
| Clone | ITEM-4 |
| Host Species | Mouse |
| Reactive Species | human, mouse |
| Isotype | IgG2bκ |
| Format | allophycocyanin (APC) conjugate |
| Size | 30 tests in 300 µL |
| Concentration | 1:11 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD266 (FN14) Antibody, anti-human/mouse, APC. Clone ITEM-4 recognizes CD266, also known as FN14, tumor necrosis factor receptor superfamily member 12A (TNFRSF12A), or tweak-receptor (TweakR). CD266 is a 14 kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) receptor superfamily and binds to TWEAK, a proinflammatory cytokine, as its only known ligand. The cytoplasmic tail of CD266 contains a TRAF binding motif and binds to TRAF1, TRAF2, TRAF3, and TRAF5. Both TWEAK dependent and independent CD266 signaling lead to activation of the NF-κB pathway. TWEAK independent signaling is shown when CD266 is ectopically overexpressed in vitro. Expression of CD266 is found on a wide variety of cells except for primary T and B cells. Elevated expression is often found in response to several growth factors, cytokines, hormones, TWEAK, after tissue injury and in solid tumors such as glioblastoma multiforme tumors. Varied functions of TWEAK signaling include promotion of wound healing and regeneration, to influence the transition from innate to adaptive immunity and regulation of cell death and tumor progression. |
| Immunogen | n/a |
| Other Names | TNFRSF12A, FN14, TWEAKR |
| Gene, Accession # | Gene ID: 51330 |
| Catalog # | 130-104-330 |
| Price | $142 |
| Order / More Info | CD266 (FN14), Human/Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Nakayama, M. et al. (2003) Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 170: 341-348. | Vince, J. E. et al. (2006) TWEAK shall inherit the earth. Cell Death Differ. 13 (11): 1842-1844. | Winkles, J. A. (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7 (5): 411-425. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies